Pfizer reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.
Britain's opposition Labour party has called for an inquiry into a potential takeover of British firm AstraZeneca by U.S. drugmaker Pfizer.
Sean Darby, Global Head of Equity Strategy at Jefferies, describes three factors that may be contributing to the flurry of deals in the pharmaceutical sector.
Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
Astrazenaca has rejected Pfizer's $106 billion bid for the company. CNBC's Meg Tirrell, and Tim Chiang, CRT Capital senior analyst, discuss Pfizer's "opportunistic" strategy, and m&a in the pharma industry.
The potential takeover of AstraZeneca is a "national interest issue" says Chuka Umunna, U.K. shadow business secretary, adding that the government should think about whether a deal with Pfizer is "good for Britain."
Savvas Neophytou, pharmaceutical analyst at Panmure Gordon, says Pfizer's increased offer for AstraZeneca is a significant step and explains that a third bid is to be expected.
American pharmaceutical giant Pfizer has hiked its takeover bid for British rival AstraZeneca to $106.5 billion. CNBC's Catherine Boyle reports.
Surani Fernando, assistant editor of Biopharm Insight, discusses whether Pfizer's updated bid for AstraZeneca will placate the U.K. government's concerns over the mega-merger.
Pfizer is set to sweeten its bid for British pharma AstraZeneca. CNBC's Catherine Boyle reports on the developments.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Two proposals in Congress are taking aim at deadly superbugs. But it's not exactly clear to some experts just what the right medicine should be.
GlaxoSmithKline's sales fell 10%, highlighting the pressures behind last week's decision to trade more than $20 billion of assets with Novartis.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Brent Saunders, CEO of Forest Labs, discusses his company's acquisition by Ireland-based Actavis.
Rhenu Bhuller, Senior VP of Healthcare at Frost & Sullivan, says the rush of deals in the pharmaceutical sector may be a manifestation of the struggles that industry players are facing.
Sachin Shah, Analyst at Albert Fried & Company, says declining sales is one of the factors fueling the flurry of deals in the pharmaceutical sector.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.